HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for evaluating liver function in patients with liver disease. The liver is the only major organ that does not have a proven function test. Once approved, HepQuant will fill this void.
Through its Investigational Device Exemption (IDE), HepQuant provides liver testing support services to liver research centers and pharmaceutical companies. The HepQuant tests are designed to evaluate the liver — and levels of hepatic impairment — regardless of the origins of the liver disease. Specifically, the tests establish a Disease Severity Index (DSI) score by measuring hepatic blood flow, portal blood flow, and portal-systemic shunt in patients suffering from chronic liver disease (CLD). HepQuant is currently filing for its FDA approval.